Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Vaccines Sales Market Report 2020-2030: Forecasts by Disease Type, Viral Diseases, Bacterial Diseases, Type of Vaccines, Distribution Channel, Age Group, Region, Competitive Landscape, COVID-19 Impact Analysis, Profiles of Leading Companies

Published by Visiongain Ltd Product code 972020
Published Content info 602 Pages
Delivery time: 1-2 business days
Price
Back to Top
Vaccines Sales Market Report 2020-2030: Forecasts by Disease Type, Viral Diseases, Bacterial Diseases, Type of Vaccines, Distribution Channel, Age Group, Region, Competitive Landscape, COVID-19 Impact Analysis, Profiles of Leading Companies
Published: September 10, 2020 Content info: 602 Pages
Description

Vaccine Sales Market our new study reveals trends, R&D progress, and predicted revenues

Where is the Vaccines market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 602 pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccines Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry.

Report Scope

  • Disease Type
    • Viral Diseases
    • Bacterial Diseases
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus
    • Measles/Mumps/Rubella
    • Rotavirus
    • Other Viral Diseases
  • Bacterial Disease
    • Pneumococcal Disease
    • Meningococcal Disease
    • Diphtheria/Tetanus/Pertussis
    • Other Bacterial Disease
  • Type Vaccines
    • Recombinant/Conjugate/Subunit
    • Inactivated
    • Live Attenuated
    • Toxoid
  • Distribution Channel
    • Hospital & Retail Pharmacies
    • Government Suppliers
    • Other Distribution Channel
  • Age Group
    • Paediatrics
    • Adults
    • Other Age Groups

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Rest of Middle East and Africa
  • Latin America
    • Brazil
    • Mexico
    • Nigeria
    • Rest of Latin America
Table of Contents
Product Code: PHA0809

Table of Contents

1. Report Overview

  • 1.1 Why You Should Buy This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Data Sources
  • 1.6 Market Evaluation & Forecasting Methodology
  • 1.7 COIVD-19 Impact Recovery Pattern Analysis
    • 1.7.1 V-Shaped Recovery
    • 1.7.2 U-Shaped Recovery
    • 1.7.3 W-Shaped Recovery
    • 1.7.4 L-Shaped Recovery
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Executive Summary

  • 2.1.1 Growing Demand for Bacterial Type to Dominate the Market
    • 2.1.1.1 Due to higher sales of pneumococcal, meningitis and DTP worldwide, the segment of bacterial diseases has a dominant market share
  • 2.1.2 By Age Group Analysis
  • 2.1.3 By Distribution Channel Analysis
  • 2.1.4 Regional Market Insight

3. Vaccine Industry Overview

  • 3.1 Industry Definitions
  • 3.2 Immune System and Vaccines
  • 3.3 How Vaccines Work
  • 3.4 Types of Immunity
    • 3.4.1 Active Immunity
    • 3.4.2 Passive Immunity
    • 3.4.3 Advantages of Vaccination
  • 3.5 History of Vaccines
  • 3.6 Rapid Manufacturing for Pandemics
    • 3.6.1 Types of Vaccine Manufacturing Methods

4. Market Dynamics

  • 4.1 Vaccine Development and Distribution Amid the COVID-19 Pandemic
  • 4.2 Market Growth Driving Factors
    • 4.2.1 Growing Vaccines Supply by UNICEF, WHO, PAHO to Aid Immunization Process
    • 4.2.2 Strong Supply Backed Up by Robust R&D to Drive the Market
    • 4.2.3 Competitive Pipeline to Expand the Market Value During the Forecast Period
    • 4.2.4 Technological Advancements such as Rapid Manufacturing and Others
    • 4.2.5 Rising Immunization Across the Globe
    • 4.2.6 Government Support for Vaccine Development
  • 4.3 Market Growth Restraining Factors
    • 4.3.1 High Cost Associated with Vaccine Dose to Limit Adoption
    • 4.3.2 Lack of Awareness in Low-Income Countries
    • 4.3.1 High Prices of Vaccines
    • 4.3.1 Rising Concerns of Associated Risk Factors
    • 4.3.2 Inadequate Vaccine Supply
  • 4.4 Growth Opportunities in the Global Market
    • 4.4.1 RNA Vaccination
    • 4.4.2 Rise of Antibiotic Resistance
    • 4.4.3 Current Situation
    • 4.4.4 Development and Launch of New Vaccines
    • 4.4.5 Increased R&D Efforts
    • 4.4.6 Increased Demand from Emerging Markets
    • 4.4.7 Government Initiatives for Increased Immunizations
    • 4.4.8 Global Alliance for Vaccines and Immunization (GAVI)
    • 4.4.9 Improving access to sustainable immunization services.
    • 4.4.10 Undulating Demand
    • 4.4.11 Supply Restraints
    • 4.4.12 Funding Trends
    • 4.4.13 Protecting the Workforce of an Economy
  • 4.5 SWOT Analysis of the World Human Vaccines Market
    • 4.5.1 Strengths
    • 4.5.2 Weaknesses
    • 4.5.3 Opportunities
    • 4.5.4 Threats
  • 4.6 STEP Analysis of the World Human Vaccines Industry and Market
    • 4.6.1 Social Factors
    • 4.6.2 Technological Forces
    • 4.6.3 Economic Factors
    • 4.6.4 Political Factors

5. COVID-19 Impact Analysis

  • 5.1 Research and Development on COVID-19

6. Global Vaccines Sales Market Outlook

  • 6.1 Market Overview
  • 6.2 Market in Terms of Value
    • 6.2.1 Market in Terms of Value (Normal Recovery)
    • 6.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.2.4 Market in Terms of Value (U-Shaped Recovery)
  • 6.3 Global Market Breakdown by Region
      • 6.3.1.1 North America is expected to dominate the global market during the forecast period
    • 6.3.1 Market in Terms of Value (Normal Recovery)
    • 6.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.4 Global Market Breakdown by Disease Type
      • 6.4.1.1 Bacterial Diseases the segment held the significant share in the overall market and is expected to offer an opportunity throughout the forecast period
    • 6.4.1 Market in Terms of Value (Normal Recovery)
    • 6.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.5 Global Market Breakdown by Viral Diseases
      • 6.5.1.1 Hepatitis Segment is expected to have the highest CAGR during forecast period.
    • 6.5.1 Human Diseases
    • 6.5.1 Market in Terms of Value (Normal Recovery)
    • 6.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.6 Global Market Breakdown by Vaccine Type
    • 6.6.1 Recombinant/Conjugate/Subunit the segment held the significant share
    • 6.6.2 Inactivated (Killed) Vaccines
    • 6.6.3 Toxoid Vaccines
    • 6.6.4 Subunit Vaccines
    • 6.6.5 Conjugate Vaccines
    • 6.6.6 Recombinant Vector Vaccines
    • 6.6.7 DNA Vaccines
    • 6.6.8 RNA Vaccines
    • 6.6.9 Adjuvants and Excipients
    • 6.6.10 Pathogen Components
    • 6.6.11 Particulate Adjuvants
    • 6.6.12 Other/Combination Vaccines
    • 6.6.13 Market in Terms of Value (Normal Recovery)
    • 6.6.14 Market in Terms of Value (V-Shaped Recovery)
    • 6.6.15 Market in Terms of Value (W-Shaped Recovery)
    • 6.6.16 Market in Terms of Value (U-Shaped Recovery)
    • 6.6.17 Market in Terms of Value (L-Shaped Recovery)
  • 6.7 Global Market Breakdown by Bacterial Disease
      • 6.7.1.1 Pneumococcal Disease is expected to offer an opportunity throughout the forecast period
    • 6.7.1 Market in Terms of Value (Normal Recovery)
    • 6.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.8 Global Market Breakdown by Distribution Channel
      • 6.8.1.1 A dominant share of the income is anticipated for hospital and retail pharmacies
    • 6.8.1 Market in Terms of Value (Normal Recovery)
    • 6.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.9 Global Market Breakdown by Age Group
    • 6.9.1 Pediatric Vaccines
    • 6.9.2 Paediatric Vaccine Trends
    • 6.9.3 Prenatal Vaccines
    • 6.9.4 Market in Terms of Value (Normal Recovery)
    • 6.9.5 Market in Terms of Value (V-Shaped Recovery)
    • 6.9.6 Market in Terms of Value (W-Shaped Recovery)
    • 6.9.7 Market in Terms of Value (U-Shaped Recovery)
    • 6.9.8 Market in Terms of Value (L-Shaped Recovery)

7. North America Vaccines Sales Market Outlook

    • 7.1.1 Growth attributed to vaccination compulsion or mandate
  • 7.1 North America Market Overview
  • 7.2 North America Market in Terms of Value
    • 7.2.1 Market in Terms of Value (Normal Recovery)
    • 7.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.3 North America Market Breakdown by Country
    • 7.3.1 Market in Terms of Value (Normal Recovery)
    • 7.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.4 U.S. Vaccine Sales Market Outlook
      • 7.4.1.1 The country is expected to offer an opportunity throughout the forecast period
    • 7.4.1 Market in Terms of Value (Normal Recovery)
    • 7.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.5 Canada Vaccine Sales Market Outlook
      • 7.5.1.1 Market is supported by consistent and sustained funding of immunization programs
    • 7.5.1 Market in Terms of Value (Normal Recovery)
    • 7.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.6 North America Market Breakdown by Disease Type
    • 7.6.1 Market in Terms of Value (Normal Recovery)
    • 7.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.7 North America Market Breakdown by Viral Diseases
    • 7.7.1 Market in Terms of Value (Normal Recovery)
    • 7.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.8 North America Market Breakdown by Vaccine Type
    • 7.8.1 Market in Terms of Value (Normal Recovery)
    • 7.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.9 North America Market Breakdown by Bacterial Disease
    • 7.9.1 Market in Terms of Value (Normal Recovery)
    • 7.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.10 North America Market Breakdown by Distribution Channel
    • 7.10.1 Market in Terms of Value (Normal Recovery)
    • 7.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.11 North America Market Breakdown by Age Group
    • 7.11.1 Market in Terms of Value (Normal Recovery)
    • 7.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.11.5 Market in Terms of Value (L-Shaped Recovery)

8. Europe Vaccines Sales Market Outlook

  • 8.1 Europe Market Overview
    • 8.1.1 A considerable growth in the vaccine market is expected in the European region.
  • 8.2 Europe Market in Terms of Value
    • 8.2.1 Market in Terms of Value (Normal Recovery)
    • 8.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.3 Europe Market Breakdown by Country
    • 8.3.1 Market in Terms of Value (Normal Recovery)
    • 8.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.4 Russia Vaccine Sales Market Outlook
      • 8.4.1.1 The Russian Federation has purchased over 90% of the total supply of the vaccines in the market
    • 8.4.1 Market in Terms of Value (Normal Recovery)
    • 8.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.5 Germany Vaccine Sales Market Outlook
    • 8.5.1.1 Germany is expected to offer an opportunity throughout the forecast period.
    • 8.5.1 Market in Terms of Value (Normal Recovery)
    • 8.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.6 UK Vaccine Sales Market Outlook
      • 8.6.1.1 The U.K. is one of the major contributors to the vaccine market
    • 8.6.1 Market in Terms of Value (Normal Recovery)
    • 8.6.1 Market in Terms of Value (V-Shaped Recovery)
    • 8.6.2 Market in Terms of Value (W-Shaped Recovery)
    • 8.6.3 Market in Terms of Value (U-Shaped Recovery)
    • 8.6.4 Market in Terms of Value (L-Shaped Recovery)
  • 8.7 France Vaccine Sales Market Outlook
      • 8.7.1.1 France is one of the major countries to produce vaccines
    • 8.7.1 Market in Terms of Value (Normal Recovery)
    • 8.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.8 Italy Vaccine Sales Market Outlook
      • 8.8.1.1 Italy is the fourth largest market for human vaccines within Europe
    • 8.8.1 Market in Terms of Value (Normal Recovery)
    • 8.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.9 Rest of Europe Vaccine Sales Market Outlook
    • 8.9.1 Market in Terms of Value (Normal Recovery)
    • 8.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.10 Europe Market Breakdown by Disease Type
    • 8.10.1 Market in Terms of Value (Normal Recovery)
    • 8.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.11 Europe Market Breakdown by Viral Disease
    • 8.11.1 Market in Terms of Value (Normal Recovery)
    • 8.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.12 Europe Market Breakdown by Vaccine Type
    • 8.12.1 Market in Terms of Value (Normal Recovery)
    • 8.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.13 Europe Market Breakdown by Bacterial Disease
    • 8.13.1 Market in Terms of Value (Normal Recovery)
    • 8.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.14 Europe Market Breakdown by Distribution Channel
    • 8.14.1 Market in Terms of Value (Normal Recovery)
    • 8.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.15 Europe Market Breakdown by Age Group
    • 8.15.1 Market in Terms of Value (Normal Recovery)
    • 8.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.15.5 Market in Terms of Value (L-Shaped Recovery)

9. Asia-Pacific Vaccines Sales Market Outlook

  • 9.1 Asia-Pacific Market Overview
  • 9.2 Asia-Pacific Market in Terms of Value
    • 9.2.1 Market in Terms of Value (Normal Recovery)
    • 9.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.3 Asia-Pacific Market Breakdown by Country
    • 9.3.1 Market in Terms of Value (Normal Recovery)
    • 9.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.4 China Vaccine Sales Market Outlook
      • 9.4.1.1 Growth prospects remain strong in the country
    • 9.4.1 Market in Terms of Value (Normal Recovery)
    • 9.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.5 Japan Vaccine Sales Market Outlook
      • 9.5.1.1 Japan is expected to offer an opportunity throughout the forecast period
    • 9.5.1 Market in Terms of Value (Normal Recovery)
    • 9.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.6 India Vaccine Sales Market Outlook
      • 9.6.1.1 The prevalence of the diseases has been quite high in India, which is driving the market growth
    • 9.6.1 Market in Terms of Value (Normal Recovery)
    • 9.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.7 South Korea Vaccine Sales Market Outlook
      • 9.7.1.1 Korea has been importing all demand for this vaccine due to a lack of homegrown technology to develop a vaccine locally
    • 9.7.1 Market in Terms of Value (Normal Recovery)
    • 9.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.8 Australia Vaccine Sales Market Outlook
      • 9.8.1.1 Australia is on track for a record number of flu vaccinations
    • 9.8.1 Market in Terms of Value (Normal Recovery)
    • 9.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.9 Rest of Asia-Pacific Vaccine Sales Market Outlook
    • 9.9.1 Market in Terms of Value (Normal Recovery)
    • 9.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.10 Asia-Pacific Market Breakdown by Disease Type
    • 9.10.1 Market in Terms of Value (Normal Recovery)
    • 9.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.11 Asia-Pacific Market Breakdown by Viral Diseases
    • 9.11.1 Market in Terms of Value (Normal Recovery)
    • 9.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.12 Asia-Pacific Market Breakdown by Vaccine Type
    • 9.12.1 Market in Terms of Value (Normal Recovery)
    • 9.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.13 Asia-Pacific Market Breakdown by Bacterial Disease
    • 9.13.1 Market in Terms of Value (Normal Recovery)
    • 9.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.14 Asia-Pacific Market Breakdown by Distribution Channel
    • 9.14.1 Market in Terms of Value (Normal Recovery)
    • 9.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.15 Asia-Pacific Market Breakdown by Age Group
    • 9.15.1 Market in Terms of Value (Normal Recovery)
    • 9.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.15.5 Market in Terms of Value (L-Shaped Recovery)

10. Middle East & Africa Vaccines Sales Market Outlook

  • 10.1 Middle East & Africa Market Overview
  • 10.2 Middle East & Africa Market in Terms of Value
    • 10.2.1 Market in Terms of Value (Normal Recovery)
    • 10.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.3 Middle East & Africa Market Breakdown by Country
    • 10.3.1 Market in Terms of Value (Normal Recovery)
    • 10.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.4 Turkey Vaccine Sales Market Outlook
    • 10.4.1 Market in Terms of Value (Normal Recovery)
    • 10.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.5 Saudi Arabia Vaccine Sales Market Outlook
      • 10.5.1.1 Healthcare is the third largest beneficiary behind education and military
    • 10.5.1 Market in Terms of Value (Normal Recovery)
    • 10.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.6 South Africa Vaccine Sales Market Outlook
      • 10.6.1.1 Pneumonia vaccine alone used up 40% of South Africa's total budget for vaccines
    • 10.6.1 Market in Terms of Value (Normal Recovery)
    • 10.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.7 Iran Vaccine Sales Market Outlook
      • 10.7.1.1. Iran's vaccine industry, has a long history and international reputation
    • 10.7.1 Market in Terms of Value (Normal Recovery)
    • 10.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.8 UAE Vaccine Sales Market Outlook
    • 10.8.1 Market in Terms of Value (Normal Recovery)
    • 10.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.9 Rest of Middle East & Africa Vaccine Sales Market Outlook
    • 10.9.1 Market in Terms of Value (Normal Recovery)
    • 10.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.10 Middle East & Africa Market Breakdown by Disease Type
    • 10.10.1 Market in Terms of Value (Normal Recovery)
    • 10.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.11 Middle East & Africa Market Breakdown by Viral Diseases
    • 10.11.1 Market in Terms of Value (Normal Recovery)
    • 10.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.12 Middle East & Africa Market Breakdown by Vaccine Type
    • 10.12.1 Market in Terms of Value (Normal Recovery)
    • 10.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.13 Middle East & Africa Market Breakdown by Bacterial Disease
    • 10.13.1 Market in Terms of Value (Normal Recovery)
    • 10.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.14 Middle East & Africa Market Breakdown by Distribution Channel
    • 10.14.1 Market in Terms of Value (Normal Recovery)
    • 10.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.15 Middle East & Africa Market Breakdown by Age Group
    • 10.15.1 Market in Terms of Value (Normal Recovery)
    • 10.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.15.5 Market in Terms of Value (L-Shaped Recovery)

11. Latin America Vaccines Sales Market Outlook

  • 11.1 Latin America Market Overview
  • 11.2 Latin America Market in Terms of Value
    • 11.2.1 Market in Terms of Value (Normal Recovery)
    • 11.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.3 Latin America Market Breakdown by Country
    • 11.3.1 Market in Terms of Value (Normal Recovery)
    • 11.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.4 Brazil Vaccine Sales Market Outlook
      • 11.4.1.1 The Brazilian human vaccines market is the largest in Latin America
    • 11.4.1 Market in Terms of Value (Normal Recovery)
    • 11.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.5 Mexico Vaccine Sales Market Outlook
    • 11.5.1 Market in Terms of Value (Normal Recovery)
    • 11.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.6 Nigeria Vaccine Sales Market Outlook
      • 11.6.1.1 The market is expected to grow at a decent growth rate during forecast period
    • 11.6.1 Market in Terms of Value (Normal Recovery)
    • 11.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.7 Rest of Latin America Vaccine Sales Market Outlook
    • 11.7.1 Market in Terms of Value (Normal Recovery)
    • 11.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.8 Latin America Market Breakdown by Disease Type
    • 11.8.1 Market in Terms of Value (Normal Recovery)
    • 11.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.9 Latin America Market Breakdown by Viral Diseases
    • 11.9.1 Market in Terms of Value (Normal Recovery)
    • 11.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.10 Latin America Market Breakdown by Vaccine Type
    • 11.10.1 Market in Terms of Value (Normal Recovery)
    • 11.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.11 Latin America Market Breakdown by Bacterial Diseases
    • 11.11.1 Market in Terms of Value (Normal Recovery)
    • 11.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.12 Latin America Market Breakdown by Distribution Channel
    • 11.12.1 Market in Terms of Value (Normal Recovery)
    • 11.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.13 Latin America Market Breakdown by Age Group
    • 11.13.1 Market in Terms of Value (Normal Recovery)
    • 11.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.13.5 Market in Terms of Value (L-Shaped Recovery)

12. Vaccines Under Research & Development

  • 12.1 Dengue Vaccine Research
    • 12.1.1 Status of vaccine development
    • 12.1.2 Challenges to Vaccine Development
    • 12.1.3 WHO activities
  • 12.2 Malaria vaccines
    • 12.2.1 Status of vaccine development
  • 12.3 HIV Vaccine Development
  • 12.4 Meningitis Vaccine Development
  • 12.5 Influenza vaccines
    • 12.5.1 Influenza Vaccine Development
    • 12.5.2 Status of Vaccine Development
    • 12.5.3 Challenges to Vaccine Development
  • 12.6 Tuberculosis Vaccine Development
  • 12.7 Zika Virus Vaccine Product Development
    • 12.7.1 Technical roadmap for Zika vaccine development
  • 12.8 Group A Streptococcus
  • 12.9 RSV Vaccine Research And Development

13. Leading Company Profiles

  • 13.1 Recent Technologies and Companies
  • 13.2 Market Share
  • 13.3 AstraZeneca
    • 13.3.1 AstraZeneca: Business Overview
    • 13.3.2 AstraZeneca: Company Financial Profile
    • 13.3.3 AstraZeneca: Product and Service Offerings
    • 13.3.4 AstraZeneca: Recent Developments
  • 13.4 Johnson & Johnson
    • 13.4.1 Johnson & Johnson: Business Overview
    • 13.4.2 Johnson & Johnson: Company Financial Profile
    • 13.4.3 Johnson & Johnson: Product and Service Offerings
    • 13.4.4 Johnson & Johnson: Recent Developments
  • 13.5 Bavarian Nordic
    • 13.5.1 Bavarian Nordic: Business Overview
    • 13.5.2 Bavarian Nordic: Company Financial Profile
    • 13.5.3 Bavarian Nordic: Product and Service Offerings
    • 13.5.4 Bavarian Nordic: Recent Developments
  • 13.6 Merck & Co.
    • 13.6.1 Merck & Co.: Business Overview
    • 13.6.2 Merck & Co.: Company Financial Profile
    • 13.6.3 Merck & co.: Product and Service Offerings
    • 13.6.4 Merck & co.: Recent Developments
  • 13.7 Takeda Pharmaceutical Company
    • 13.7.1 Takeda Pharmaceutical Company: Business Overview
    • 13.7.2 Takeda Pharmaceutical Company: Company Financial Profile
    • 13.7.3 Takeda Pharmaceutical Company: Product and Service Offerings
    • 13.7.4 Takeda Pharmaceutical Company: Recent Developments
  • 13.8 Roche Holding AG
    • 13.8.1 Roche Holding AG: Business Overview
    • 13.8.2 Roche Holding AG: Company Financial Profile
    • 13.8.3 Roche Holding AG: Product and Service Offerings
    • 13.8.4 Roche Holding AG: Recent Developments
  • 13.9 GlaxoSmithKline PLC (GSK)
    • 13.9.1 GlaxoSmithKline PLC (GSK): Business Overview
    • 13.9.2 GlaxoSmithKline PLC (GSK): Company Financial Profile
    • 13.9.3 GlaxoSmithKline PLC (GSK): Product and Service Offerings
    • 13.9.4 GlaxoSmithKline PLC (GSK): Recent Developments
  • 13.10 Bayer Inc.
    • 13.10.1 Bayer Inc.: Business Overview
    • 13.10.2 Bayer Inc.: Company Financial Profile
    • 13.10.3 Bayer Inc.: Product and Service Offerings
    • 13.10.4 Bayer Inc.: Recent Developments
  • 13.11 Eli Lilly and Company
    • 13.11.1 Eli Lilly and Company: Business Overview
    • 13.11.2 Eli Lilly and Company: Company Financial Profile
    • 13.11.3 Eli Lilly and Company: Product and Service Offerings
    • 13.11.4 Eli Lilly and Company: Recent Developments
  • 13.12 Bristol-Myers Squibb
    • 13.12.1 Bristol-Myers Squibb: Business Overview
    • 13.12.2 Bristol-Myers Squibb: Company Financial Profile
    • 13.12.3 Bristol-Myers Squibb: Product and Service Offerings
    • 13.12.4 Bristol-Myers Squibb: Recent Developments
  • 13.13 Pfizer Inc.
    • 13.13.1 Pfizer Inc.: Business Overview
    • 13.13.2 Pfizer Inc.: Company Financial Profile
    • 13.13.3 Pfizer Inc.: Product and Service Offerings
    • 13.13.4 Pfizer Inc.: Recent Developments
  • 13.14 Emergent BioSolutions Inc.
    • 13.14.1 Emergent BioSolutions Inc.: Business Overview
    • 13.14.2 Emergent BioSolutions Inc.: Company Financial Profile
    • 13.14.3 Emergent BioSolutions Inc.: Product and Service Offerings
    • 13.14.4 Emergent BioSolutions Inc.: Recent Developments
  • 13.15 Fresenius SE & Co KGaA
    • 13.15.1 Fresenius SE & Co KGaA: Business Overview
    • 13.15.2 Fresenius SE & Co KGaA: Company Financial Profile
    • 13.15.3 Fresenius SE & Co KGaA: Product and Service Offerings
    • 13.15.4 Fresenius SE & Co KGaA: Recent Developments
  • 13.16 Sanofi
    • 13.16.1 Sanofi: Business Overview
    • 13.16.2 Sanofi: Company Financial Profile
    • 13.16.3 Sanofi: Product and Service Offerings
    • 13.16.4 Sanofi: Recent Developments
  • 13.17 BiondVaxPharmaceuticals Ltd.
    • 13.17.1 BiondVax Pharmaceuticals Ltd.: Business Overview
    • 13.17.2 BiondVax Pharmaceuticals Ltd.: Company Financial Profile
    • 13.17.3 BiondVax Pharmaceuticals Ltd.: Product and Service Offerings
    • 13.17.4 BiondVax Pharmaceuticals Ltd.: Recent Developments

14. Conclusion & Recommendations

Back to Top